Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded
| 24-07-03 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24-04-24 | Antibe Announces Appointment of Receiver | BU |
| 24-04-22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 24-04-19 | Antibe Provides Update on CCAA Proceedings | BU |
| 24-04-16 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 2015-11-30 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24-03-07 | Option | Chief Executive Officer | 35,000 | 0.0665% | ||
| 24-03-07 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 24-03-07 | Option | Chief Technology Officer | 9,000 | 0.0171% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +2.87% | +4.57% | +68.97% | +119.22% | 56.65B | |
| +4.00% | +7.51% | +63.67% | +68.77% | 47.49B | |
| -0.77% | -0.67% | -15.34% | -15.95% | 22.81B | |
| +2.93% | +1.17% | -3.97% | +384.78% | 21.37B | |
| +0.72% | +3.26% | +26.53% | -17.88% | 16.12B | |
| +1.16% | +3.86% | +20.23% | -36.42% | 15.56B | |
| -1.08% | -3.11% | +27.20% | +158.30% | 12.91B | |
| +3.30% | +15.02% | +133.24% | +273.89% | 12.86B | |
| 0.00% | -7.52% | +20.09% | - | 11.67B | |
| Average | +1.35% | +2.16% | +37.85% | +116.84% | 24.16B | |
| Weighted average by Cap. | +2.12% | +3.27% | +43.86% | +109.78% |
Employees
11
